Taysha Gene Ther­a­pies looks to build on rapid IPO with $85M dev-man­u­fac­tur­ing plant in North Car­oli­na

Taysha Gene Ther­a­pies went pub­lic with a bang ear­li­er this year with a $157 mil­lion IPO just five months af­ter its Se­ries A fi­nanc­ing. Now, with the help of the city of Durham, North Car­oli­na, Taysha is plot­ting an ex­pan­sive de­vel­op­ment and man­u­fac­tur­ing fa­cil­i­ty to ramp up sup­plies for the clin­ic — and po­ten­tial­ly the com­mer­cial mar­ket.

The new 187,000-square-foot cGMP plant will cre­ate rough­ly 200 jobs for Taysha Gene Ther­a­pies, which formed in late 2019 with the sole fo­cus of de­vel­op­ing ther­a­peu­tics for mono­genic dis­eases us­ing an ade­no-as­so­ciate virus method­ol­o­gy. The an­nounce­ment con­tin­ues a rapid as­cent for Taysha, which launched Se­ries A fi­nanc­ing just in April, and a mere five months lat­er had its own Nas­daq tick­er, of­fer­ing a $157 mil­lion IPO and pric­ing shares at $20 apiece.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER